MA41265A - Compositions pour administration de médicaments iléo-jéjunal. - Google Patents

Compositions pour administration de médicaments iléo-jéjunal.

Info

Publication number
MA41265A
MA41265A MA041265A MA41265A MA41265A MA 41265 A MA41265 A MA 41265A MA 041265 A MA041265 A MA 041265A MA 41265 A MA41265 A MA 41265A MA 41265 A MA41265 A MA 41265A
Authority
MA
Morocco
Prior art keywords
iléo
jejunal
drugs
administration
compositions
Prior art date
Application number
MA041265A
Other languages
English (en)
Other versions
MA41265B1 (fr
Inventor
Bret Berner
Mohammad Reza Masjedizadeh
Philip A Nunn
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MA41265A publication Critical patent/MA41265A/fr
Publication of MA41265B1 publication Critical patent/MA41265B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA41265A 2014-12-24 2015-12-23 Compositions pour administration de médicaments iléo-jéjunal. MA41265B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096812P 2014-12-24 2014-12-24
PCT/US2015/000515 WO2016105582A1 (fr) 2014-12-24 2015-12-23 Compositions pour administration de médicaments iléo-jéjunal.

Publications (2)

Publication Number Publication Date
MA41265A true MA41265A (fr) 2017-10-31
MA41265B1 MA41265B1 (fr) 2023-05-31

Family

ID=55361929

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41265A MA41265B1 (fr) 2014-12-24 2015-12-23 Compositions pour administration de médicaments iléo-jéjunal.

Country Status (16)

Country Link
US (1) US20180193274A1 (fr)
EP (1) EP3236943B1 (fr)
JP (1) JP6687248B2 (fr)
DK (1) DK3236943T3 (fr)
ES (1) ES2942642T3 (fr)
FI (1) FI3236943T3 (fr)
HK (1) HK1245071A1 (fr)
HR (1) HRP20230305T1 (fr)
HU (1) HUE061809T2 (fr)
LT (1) LT3236943T (fr)
MA (1) MA41265B1 (fr)
PL (1) PL3236943T3 (fr)
PT (1) PT3236943T (fr)
RS (1) RS64139B1 (fr)
SI (1) SI3236943T1 (fr)
WO (1) WO2016105582A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3181567T3 (da) 2012-09-10 2019-06-11 Principia Biopharma Inc Pyrazolopyrimidinforbindelser som kinasehæmmere
MX367918B (es) 2013-04-25 2019-09-11 Beigene Ltd Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
CA3028169A1 (fr) 2016-06-29 2018-01-04 Principia Biopharma Inc. Formulations a liberation modifiee a base de 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidine-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetane-3-yl)piperazin e-1-yl]pent-2-enenitrile
WO2018007885A1 (fr) 2016-07-05 2018-01-11 Beigene, Ltd. Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer.
CA3033827A1 (fr) 2016-08-16 2018-02-22 Beigene, Ltd. Forme cristalline de (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyle)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa preparation et ses utilisations
EP4353747A3 (fr) 2016-08-19 2024-06-26 BeiGene Switzerland GmbH Combinaison de zacuturinib avec un anticorps anti-cd20 ou anti-pd-1 pour une utilisation dans le traitement du cancer
CN106588937B (zh) * 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
WO2018137681A1 (fr) 2017-01-25 2018-08-02 Beigene, Ltd. Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, préparation et utilisations associées
EP3645569A4 (fr) 2017-06-26 2021-03-24 BeiGene, Ltd. Immunothérapie pour carcinome hépatocellulaire
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
CN114478544B (zh) * 2017-09-28 2023-06-16 上海海雁医药科技有限公司 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2019142207A1 (fr) 2018-01-20 2019-07-25 Natco Pharma Limited Compositions pharmaceutiques comprenant de l'ibrutinib
SG11202102116XA (en) * 2018-09-18 2021-04-29 Beijing Innocare Pharma Tech Co Ltd Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
WO2020093896A1 (fr) * 2018-11-06 2020-05-14 Beijing Innocare Pharma Tech Co., Ltd. Dispersion solide amorphe de 6-(1-acryloylpipéridine-4-yl)-2-(4-phénoxyphényl) nicotinamide
WO2020102304A1 (fr) * 2018-11-13 2020-05-22 Rain Therapeutics Inc. Combinaison d'un inhibiteur de kinase et d'un électrolyte, compositions et procédés la comprenant
CN109851725A (zh) * 2018-12-29 2019-06-07 华南理工大学 纳米纤维素-聚丙烯酰胺-明胶复合水凝胶、其制备方法及应用
US20240075042A1 (en) * 2020-11-02 2024-03-07 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN113855695B (zh) * 2021-11-01 2023-06-06 上海理工大学 一种结肠释药口服复方药物组合物及其制备方法
CN114181159B (zh) * 2021-12-28 2024-02-20 南通大学 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
CN116473923B (zh) * 2023-05-29 2024-05-14 杭州剂泰医药科技有限责任公司 一种奈拉替尼固体分散体组合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6506555B2 (ja) * 2011-10-19 2019-04-24 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US20160045503A1 (en) * 2012-06-18 2016-02-18 Principia Biopharma Inc. Formulations containing reversible covalent compounds
WO2014004707A1 (fr) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprenant de l'ibrutinib
DK3181567T3 (da) * 2012-09-10 2019-06-11 Principia Biopharma Inc Pyrazolopyrimidinforbindelser som kinasehæmmere
MX2015008625A (es) * 2013-01-05 2015-09-23 Elcelyx Therapeutics Inc Composicion de liberacion demorada que comprende biguanida.

Also Published As

Publication number Publication date
HUE061809T2 (hu) 2023-08-28
DK3236943T3 (da) 2023-04-11
EP3236943A1 (fr) 2017-11-01
PL3236943T3 (pl) 2023-05-29
HRP20230305T1 (hr) 2023-05-26
JP6687248B2 (ja) 2020-04-22
PT3236943T (pt) 2023-04-20
EP3236943B1 (fr) 2023-01-25
HK1245071A1 (zh) 2018-08-24
RS64139B1 (sr) 2023-05-31
FI3236943T3 (fi) 2023-04-27
JP2018500353A (ja) 2018-01-11
WO2016105582A1 (fr) 2016-06-30
LT3236943T (lt) 2023-04-11
SI3236943T1 (sl) 2023-06-30
US20180193274A1 (en) 2018-07-12
ES2942642T3 (es) 2023-06-05
MA41265B1 (fr) 2023-05-31

Similar Documents

Publication Publication Date Title
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
IL265360B (en) Pharmaceutical composition
DK3529248T3 (da) Farmaceutiske sammensætninger
BR112016023628A2 (pt) composições farmacêuticas.
IL265260B (en) pharmaceutical preparations
ZA201901590B (en) Liquid pharmaceutical composition
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112016026879A2 (pt) Composição farmacêutica líquida
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
ZA201901736B (en) Liquid pharmaceutical composition
DK3237045T3 (da) Indretning til indgivelse af lægemidler
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
IL262654A (en) Pharmacy preparation
IL265349A (en) Pharmaceutical composition
DK3199161T3 (da) Farmaceutisk præparat
DK3145488T3 (da) Flydende farmaceutiske forbindelse
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615917D0 (en) Pharmaceutical composition
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
IL263999A (en) Pharmaceutical compositions
GB201615910D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid